# Myron R Szewczuk

## List of Publications by Year in Descending Order



| | | | |
|---|---|---|---|
| 70 papers | 1,626 citations | 23 h-index | 38 g-index |
| 72 ext. papers | 1,930 ext. citations | 5.2 avg, IF | 4.89 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 70 | Next Generation of Cancer Drug Repurposing: Therapeutic Combination of Aspirin and Oseltamivir Phosphate Potentiates Gemcitabine to Disable Key Survival Pathways Critical for Pancreatic Cancer Progression.. *Cancers*, **2022**, 14, | 6.6 | 2 |
| 69 | 3D Multicellular Stem-Like Human Breast Tumor Spheroids Enhance Tumorigenicity of Orthotopic Xenografts in Athymic Nude Rat Model. *Cancers*, **2021**, 13, | 6.6 | 3 |
| 68 | Drug delivery systems in cancer therapy **2021**, 423-454 | | 1 |
| 67 | Folic Acid-Functionalized Nanomedicine: Folic Acid Conjugated Copolymer and Folate Receptor Interactions Disrupt Receptor Functionality Resulting in Dual Therapeutic Anti-Cancer Potential in Breast and Prostate Cancer. *Bioconjugate Chemistry*, **2021**, 32, 512-522 | 6.3 | 2 |
| 66 | Next-generation multimodality of nutrigenomic cancer therapy: sulforaphane in combination with acetazolamide actively target bronchial carcinoid cancer in disabling the PI3K/Akt/mTOR survival pathway and inducing apoptosis. *Oncotarget*, **2021**, 12, 1470-1489 | 3.3 | 6 |
| 65 | The Next-Generation of Combination Cancer Immunotherapy: Epigenetic Immunomodulators Transmogrify Immune Training to Enhance Immunotherapy. *Cancers*, **2021**, 13, | 6.6 | 1 |
| 64 | Formulation, Characterization and Cytotoxicity Effects of Novel Thymoquinone-PLGA-PF68 Nanoparticles. *International Journal of Molecular Sciences*, **2021**, 22, | 6.3 | 1 |
| 63 | A Triple Combination of Metformin, Acetylsalicylic Acid, and Oseltamivir Phosphate Impacts Tumour Spheroid Viability and Upends Chemoresistance in Triple-Negative Breast Cancer. *Drug Design, Development and Therapy*, **2020**, 14, 1995-2019 | 4.4 | 8 |
| 62 | Novel Molecular Mechanism of Aspirin and Celecoxib Targeting Mammalian Neuraminidase-1 Impedes Epidermal Growth Factor Receptor Signaling Axis and Induces Apoptosis in Pancreatic Cancer Cells. *Drug Design, Development and Therapy*, **2020**, 14, 4149-4167 | 4.4 | 8 |
| 61 | The crucial role of primary care providers in the long-term follow-up of adult survivors of childhood cancer. *Cancer Management and Research*, **2019**, 11, 3411-3418 | 3.6 | 1 |
| 60 | Current Challenges in Cancer Immunotherapy: Multimodal Approaches to Improve Efficacy and Patient Response Rates. *Journal of Oncology*, **2019**, 2019, 4508794 | 4.5 | 115 |
| 59 | Non-Nutritive Sweeteners and Their Implications on the Development of Metabolic Syndrome. *Nutrients*, **2019**, 11, | 6.7 | 22 |
| 58 | Targeting the Tumor Microenvironment to Overcome Resistance to Therapy. *Resistance To Targeted Anti-cancer Therapeutics*, **2019**, 35-61 | 0.3 | 1 |
| 57 | Next-Generation Multimodality of Nanomedicine Therapy: Size and Structure Dependence of Folic Acid Conjugated Copolymers Actively Target Cancer Cells in Disabling Cell Division and Inducing Apoptosis. *Cancers*, **2019**, 11, | 6.6 | 6 |
| 56 | Therapeutic Options for Metastatic Breast Cancer. *Advances in Experimental Medicine and Biology*, **2019**, 1152, 131-172 | 3.6 | 14 |
| 55 | Introduction to the Acquisition of Resistance to Targeted Therapy. *Resistance To Targeted Anti-cancer Therapeutics*, **2019**, 1-33 | 0.3 | 2 |
| 54 | Computer Vision for Detecting and Measuring Multicellular Tumor Shperoids of Prostate Cancer **2019**, | | 1 |

| | | | |
|---|---|---|---|
| 53 | Impact of Fucosylation on Self-Assembly of Prostate and Breast Tumor Spheroids by Using Cyclo-RGDfK(TPP) Peptide and Image Object Detection. *OncoTargets and Therapy*, **2019**, 12, 11153-11173 | 4.4 | 3 |
| 52 | Biased G protein-coupled receptor agonism mediates Neu1 sialidase and matrix metalloproteinase-9 crosstalk to induce transactivation of insulin receptor signaling. *Cellular Signalling*, **2018**, 43, 71-84 | 4.9 | 28 |
| 51 | The Biased G-Protein-Coupled Receptor Agonism Bridges the Gap between the Insulin Receptor and the Metabolic Syndrome. *International Journal of Molecular Sciences*, **2018**, 19, | 6.3 | 11 |
| 50 | Therapeutic potential of medicinal marijuana: an educational primer for health care professionals. *Drug, Healthcare and Patient Safety*, **2018**, 10, 45-66 | 1.6 | 30 |
| 49 | Recent advances in "smart" delivery systems for extended drug release in cancer therapy. *International Journal of Nanomedicine*, **2018**, 13, 4727-4745 | 7.3 | 109 |
| 48 | Functionalized Folic Acid-Conjugated Amphiphilic Alternating Copolymer Actively Targets 3D Multicellular Tumour Spheroids and Delivers the Hydrophobic Drug to the Inner Core. *Nanomaterials*, **2018**, 8, | 5.4 | 10 |
| 47 | Oseltamivir phosphate released from injectable Pickering emulsions over an extended term disables human pancreatic cancer cell survival. *Oncotarget*, **2018**, 9, 12754-12768 | 3.3 | 11 |
| 46 | Agonist-Biased Signaling via Matrix Metalloproteinase-9 Promotes Extracellular Matrix Remodeling. *Cells*, **2018**, 7, | 7.9 | 16 |
| 45 | Combinatorial and sequential delivery of gemcitabine and oseltamivir phosphate from implantable poly(d,l-lactic-co-glycolic acid) cylinders disables human pancreatic cancer cell survival. *Drug Design, Development and Therapy*, **2017**, 11, 2239-2250 | 4.4 | 12 |
| 44 | Sialylation facilitates self-assembly of 3D multicellular prostaspheres by using cyclo-RGDfK(TPP) peptide. *OncoTargets and Therapy*, **2017**, 10, 2427-2447 | 4.4 | 13 |
| 43 | Alternative therapies for metastatic breast cancer: multimodal approach targeting tumor cell heterogeneity. *Breast Cancer: Targets and Therapy*, **2017**, 9, 85-93 | 3.9 | 16 |
| 42 | Oseltamivir-conjugated polymeric micelles prepared by RAFT living radical polymerization as a new active tumor targeting drug delivery platform. *Biomaterials Science*, **2016**, 4, 511-21 | 7.4 | 13 |
| 41 | Sialylation transmogrifies human breast and pancreatic cancer cells into 3D multicellular tumor spheroids using cyclic RGD-peptide induced self-assembly. *Oncotarget*, **2016**, 7, 66119-66134 | 3.3 | 19 |
| 40 | Neuraminidase-1: a novel therapeutic target in multistage tumorigenesis. *Oncotarget*, **2016**, 7, 40860-40881 | 3.3 | 45 |
| 39 | Folic acid-conjugated amphiphilic alternating copolymer as a new active tumor targeting drug delivery platform. *Drug Design, Development and Therapy*, **2016**, 10, 4101-4110 | 4.4 | 27 |
| 38 | Therapeutic designed poly (lactic-co-glycolic acid) cylindrical oseltamivir phosphate-loaded implants impede tumor neovascularization, growth and metastasis in mouse model of human pancreatic carcinoma. *Drug Design, Development and Therapy*, **2015**, 9, 4573-86 | 4.4 | 7 |
| 37 | A novel insulin receptor-signaling platform and its link to insulin resistance and type 2 diabetes. *Cellular Signalling*, **2014**, 26, 1355-68 | 4.9 | 61 |
| 36 | Oseltamivir phosphate monotherapy ablates tumor neovascularization, growth, and metastasis in mouse model of human triple-negative breast adenocarcinoma. *Breast Cancer: Targets and Therapy*, **2014**, 6, 191-203 | 3.9 | 19 |

| | | | |
|---|---|---|---|
| 35 | Transcriptional factor snail controls tumor neovascularization, growth and metastasis in mouse model of human ovarian carcinoma. *Clinical and Translational Medicine*, **2014**, 3, 28 | 5.7 | 24 |
| 34 | Therapeutic targeting of Neu1 sialidase with oseltamivir phosphate (Tamiflu ) disables cancer cell survival in human pancreatic cancer with acquired chemoresistance. *OncoTargets and Therapy*, **2014** , 7, 117-34 | 4.4 | 32 |
| 33 | A novel epidermal growth factor receptor-signaling platform and its targeted translation in pancreatic cancer. *Cellular Signalling*, **2013**, 25, 2587-603 | 4.9 | 55 |
| 32 | Neu1 sialidase and matrix metalloproteinase-9 cross-talk regulates nucleic acid-induced endosomal TOLL-like receptor-7 and -9 activation, cellular signaling and pro-inflammatory responses. *Cellular Signalling*, **2013**, 25, 2093-105 | 4.9 | 37 |
| 31 | A novel G-protein-coupled receptor-signaling platform and its targeted translation in human disease. *Research and Reports in Biochemistry*, **2013**, 17 | | 1 |
| 30 | G-protein coupled receptor agonists mediate Neu1 sialidase and matrix metalloproteinase-9 cross-talk to induce transactivation of TOLL-like receptors and cellular signaling. *Cellular Signalling*, **2012**, 24, 2035-42 | 4.9 | 43 |
| 29 | The TLR2 agonists lipoteichoic acid and Pam3CSK4 induce greater pro-inflammatory responses than inactivated Mycobacterium butyricum. *Cellular Immunology*, **2012**, 280, 101-7 | 4.4 | 18 |
| 28 | Neu1 sialidase and matrix metalloproteinase-9 cross-talk is essential for Toll-like receptor activation and cellular signaling. *Journal of Biological Chemistry*, **2011**, 286, 36532-49 | 5.4 | 59 |
| 27 | Regulation of phagocytosis in macrophages by neuraminidase 1. *Journal of Biological Chemistry*, **2010**, 285, 206-15 | 5.4 | 52 |
| 26 | Detection of Neu1 sialidase activity in regulating Toll-like receptor activation. *Journal of Visualized Experiments*, **2010**, | 1.6 | 26 |
| 25 | Thymoquinone from nutraceutical black cumin oil activates Neu4 sialidase in live macrophage, dendritic, and normal and type I sialidosis human fibroblast cells via GPCR Galphai proteins and matrix metalloproteinase-9. *Glycoconjugate Journal*, **2010**, 27, 329-48 | 3 | 21 |
| 24 | Thymoquinone-induced Neu4 sialidase activates NFB in macrophage cells and pro-inflammatory cytokines in vivo. *Glycoconjugate Journal*, **2010**, 27, 583-600 | 3 | 18 |
| 23 | Neu1 desialylation of sialyl alpha-2,3-linked beta-galactosyl residues of TOLL-like receptor 4 is essential for receptor activation and cellular signaling. *Cellular Signalling*, **2010**, 22, 314-24 | 4.9 | 139 |
| 22 | Neu1 sialidase and matrix metalloproteinase-9 cross-talk is essential for neurotrophin activation of Trk receptors and cellular signaling. *Cellular Signalling*, **2010**, 22, 1193-205 | 4.9 | 50 |
| 21 | Dependence of pathogen molecule-induced toll-like receptor activation and cell function on Neu1 sialidase. *Glycoconjugate Journal*, **2009**, 26, 1197-212 | 3 | 90 |
| 20 | Dependence of neurotrophic factor activation of Trk tyrosine kinase receptors on cellular sialidase. *Glycobiology*, **2007**, 17, 10-24 | 5.8 | 42 |
| 19 | Trypanosome trans-sialidase mediates neuroprotection against oxidative stress, serum/glucose deprivation, and hypoxia-induced neurite retraction in Trk-expressing PC12 cells. *Glycobiology*, **2007**, 17, 725-34 | 5.8 | 25 |
| 18 | Trypanosome trans-sialidase targets TrkA tyrosine kinase receptor and induces receptor internalization and activation. *Glycobiology*, **2004**, 14, 987-98 | 5.8 | 27 |

| | | | |
|---|---|---|---|
| 17 | Natural killer cell activity in murine muscular dystrophy. III. NK-sensitive myoblast cells and lack of NK activity in beige/dystrophic hybrid mice. *Cellular Immunology*, **1986**, 100, 20-33 | 4.4 | |
| 16 | Natural killer cells in murine muscular dystrophy. IV. Characterization of Percoll fractionated splenic and thymic natural killer cells and natural killer-sensitive thymocyte targets. *Clinical Immunology and Immunopathology*, **1986**, 41, 116-29 | | 2 |
| 15 | Analysis of serum antibody repertoires by isoelectric focusing and capillary blotting onto nitrocellulose paper. *Journal of Immunological Methods*, **1986**, 89, 201-5 | 2.5 | 10 |
| 14 | Age-related strain differences in the development of auto-anti-idiotypic antibody regulation in the splenic and mucosal-associated lymphoid systems. *Gerontology*, **1985**, 31, 251-62 | 5.5 | 3 |
| 13 | Strain differences in the development of auto-anti-idiotypic antibody regulation with age: genetic linkage to the Igh-C locus. *Cellular Immunology*, **1984**, 84, 393-402 | 4.4 | 4 |
| 12 | Natural killer (NK) cell activity in murine muscular dystrophy. II. Age-related tissue distribution and enhanced NK activity in the thymus of dystrophic mice. *Clinical Immunology and Immunopathology*, **1984**, 33, 144-53 | | 3 |
| 11 | Aging, idiotype repertoire shifts, and compartmentalization of the mucosal-associated lymphoid system. *Advances in Immunology*, **1984**, 36, 143-88 | 5.6 | 53 |
| 10 | DIVERGENT SHIFTS IN T-LYMPHOCYTE SUBPOPULATIONS AMONG MUCOSAL LYMPHOID TISSUES OF MICE WITH INCREASING AGE*. *Annals of the New York Academy of Sciences*, **1983**, 409, 806-807 | 6.5 | 5 |
| 9 | IMPAIRMENT OF SECONDARY MEMORY B-LYMPHOCYTES BY ORAL IMMUNIZATION OF AGING MICE*. *Annals of the New York Academy of Sciences*, **1983**, 409, 887-887 | 6.5 | |
| 8 | Aging and the mucosal-associated lymphoid system. *Annals of the New York Academy of Sciences*, **1983**, 409, 333-44 | 6.5 | 13 |
| 7 | Selective suppression by auto-anti-idiotypic antibody of B-cell idiotype repertoires generated after stimulation with the same hapten on T-dependent and T-independent carriers. *Cellular Immunology*, **1983**, 82, 282-91 | 4.4 | 6 |
| 6 | Enhanced natural killer (NK) cell activity and NK-sensitive thymic cells in murine muscular dystrophy. *Cellular Immunology*, **1983**, 82, 316-25 | 4.4 | 6 |
| 5 | Evidence for histamine-induced auto-anti-idiotypic antibody immunoregulation in vivo. *Cellular Immunology*, **1981**, 65, 152-65 | 4.4 | 9 |
| 4 | Ontogeny of B lymphocyte function. X. Strain differences in maturation of the capacity of the B lymphocyte population to produce a high-affinity antibody response. *European Journal of Immunology*, **1981**, 11, 32-8 | 6.1 | 10 |
| 3 | Lack of age-associated auto-anti-idiotypic antibody regulation in mucosal-associated lymph nodes. *European Journal of Immunology*, **1981**, 11, 650-6 | 6.1 | 9 |
| 2 | Ontogeny of B lymphocyte function. VIII. Failure of thymus cells from aged donors to induce the functional maturation of B lymphocytes from immature donors. *European Journal of Immunology*, **1980**, 10, 918-23 | 6.1 | 14 |
| 1 | Loss of immune competence with age may be due to auto-anti-idiotypic antibody regulation. *Nature*, **1980**, 286, 164-6 | 50.4 | 76 |